-- Cautious spending environment has resulted in several joint ventures
MOUNTAIN VIEW, California, March 6, 2013 /PRNewswire/ -- Decreasing exit opportunities and a challenging fundraising environment give pause to venture capitalists (VCs) in the North American healthcare industry. The increase in average deal value implies that VCs are choosing their companies prudently, despite reduction in the overall volume and value of deals.
New analysis from Frost & Sullivan's (http://www.financialservices.frost.com) Analysis of Venture Capital Investment Trends in the North American Healthcare Industry research reveals companies that have completed Phase 2 or are nearing Phase 3 of trials are attracting VC investors because of the shorter exit period and fewer failure risks.
If you are interested in more information on this analysis, please email Britni Myers, Corporate Communications, at email@example.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.
"Government initiatives such as tax exemptions, lower interest rates and subsidies will go a long way," said Frost & Sullivan Business and Financial Services Research Analyst Dr. E. Saneesh. "This support will prompt VCs to invest more in new products and technologies."
Owing to the current straitened circumstances, an increasing number of VCs are signing joint investment deals and forming partnerships with bigger healthcare companies, including pharmaceutical majors and medical technology companies.
However, the long drug development period, increasing clinical trial risks, stricter regulations, and decreasing initial public offerings (IPOs) make VCs skeptical about investing in biotechnology and pharmaceutical start-ups. Further, as the pharmaceutical and biotechnology sectors become more mature, start-ups will require heavier investments. This is causing the pharmaceutical and biotechnology sectors to change from VC-driven to focus more on private equity funded opportunities.
"Increased competition and uncertain margins compel pharmaceutical companies to adopt alternate methods," noted Dr. Saneesh. "These alternatives include strategic investments and venture investment arms to endow biotechnology companies that have attractive products in the pipeline."
Overall, innovations in drug delivery technologies, structural remodeling, and product stabilization are attractive to investors. Mobile health (mHealth) and healthcare IT, which can reduce delivery costs, will also draw VC funding.
Analysis of Venture Capital Investment Trends in the North American Healthcare Industry is part of the Business and Financial Services subscription, which also includes research services in the following markets: Private Equity and Venture Capital Investment Trends in the Financial Services Industry in North America, Financial Assessment of the Global Insurance Industry, Clinical Trials Market in APAC, and Mergers and Acquisitions in the Asia-Pacific (APAC) Healthcare Industry. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
Frost & Sullivan's Business and Financial Services group serves clients around the world in all aspects of financial analysis, market research and monitoring, due diligence, idea generation, opportunity analysis, investment valuation, and other proprietary research.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Analysis of Venture Capital Investment Trends in the North American Healthcare Industry
SOURCE Frost & Sullivan